Erratum: Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial (JAMA. (2016) 316, 4 (401-409) DOI: 10.1001/jama.2016.9839);Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 316, Issue 4, 2016, Pages 401-409

  Brown, Paul D ^a   Jaeckle, Kurt ^c   Ballman, Karla V ^b   Farace, Elana ^d   Cerhan, Jane H ^b   Keith Anderson, S ^b   Carrero, Xiomara W ^b   Barker, Fred G ^e   Deming, Richard ^f   Burri, Stuart H ^g   Ménard, Cynthia ^h,i   Chung, Caroline ^h   Stieber, Volker W ^j   Pollock, Bruce E ^b   Galanis, Evanthia ^b   Buckner, Jan C ^b   Asher, Anthony L ^g,k  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MERCY MEDICAL CENTER   (United States)

^g LEVINE CANCER INSTITUTE   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j FORSYTH MEDICAL CENTER   (United States)

^k CAROLINA NEUROSURGERY AND SPINE ASSOCIATES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN DYSFUNCTION; BRAIN METASTASIS; BRAIN NECROSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITION; CONTROLLED STUDY; DETERIORATION; FEMALE; FUNCTIONAL ASSESSMENT; GAMMA RADIATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; AGED; BRAIN NEOPLASMS; CLINICAL TRIAL; COGNITION DISORDERS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSURGERY; SECONDARY; SKULL IRRADIATION; SURVIVAL ANALYSIS; SURVIVOR; TIME FACTOR;

ADULT; AGED; BRAIN NEOPLASMS; COGNITION; COGNITION DISORDERS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RADIOSURGERY; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS;

EID: 84979735756     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.9890     Document Type: Erratum

References (25)

1. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-2491.
2. Frisk G, Svensson T, Bäcklund LM, Lidbrink E, Blomqvist P, Smedby KE. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer. 2012;106 (11):1850-1853.
3. Nabors LB, Portnow J, Ammirati M, et al. Central nervous system cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13(10):1191-1202.
4. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037-1044.
5. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy vs observation after radiosurgery or surgical resection of 1 to 3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141.
6. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388-1395.
7. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol. 2007;25(10):1260-1266.
8. Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol. 2015;33(15):1653-1659.
9. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale: development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75(5):1151-1161.
10. Wade DT. Measurement in neurological rehabilitation. Curr Opin Neurol Neurosurg. 1992;5 (5):682-686.
11. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006;24 (8):1305-1309.
12. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22(1):157-165.
13. Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst. 2002;94(14):1044-1045.
14. Bailar JC III, Smith EM. Progress against cancer? N Engl J Med. 1986;314(19):1226-1232.
15. Gray RJ. A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
16. Brown PD, Ballman KV, Rummans TA, et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol. 2006;76(3):283-291.
17. R Core Team 2014. A language and environment for statistical computing. http://www.R-project.org/.
18. Brown PD, Buckner JC, O'Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol. 2003;21(13):2519-2524.
19. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-395.
20. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789-796.
21. Brown PD, Pugh S, Laack NN, et al; Radiation Therapy Oncology Group. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429-1437.
22. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810-3816.
23. Miller FG, Kaptchuk TJ. Sham procedures and the ethics of clinical trials. J R Soc Med. 2004;97 (12):576-578.
24. Onodera S, Aoyama H, Tha KK, et al. The value of 4-month neurocognitive function as an endpoint in brain metastases trials. J Neurooncol. 2014;120 (2):311-319.
25. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy vs observation in patients with 1 to 3 brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65-72.